Affiliation:
1. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
Abstract
Abstract
Thrombotic complications are the primary contributor to morbidity and mortality in essential thrombocythemia (ET) and polycythemia vera (PV). Cytoreductive therapy is the main tool for primary or tertiary thrombosis prevention in these diseases. In general, high-thrombotic-risk patients and those with symptoms that may be ameliorated from cytoreductive therapy are candidates for this treatment, although the decision is highly individualized. Approved options for cytoreduction in ET and PV include hydroxyurea, long-acting interferons, anagrelide in ET, and ruxolitinib in PV. Selecting the ideal agent requires careful consideration of the toxicity profiles and individual treatment goals. In this review the existing literature on cytoreductive decisions in ET and PV is summarized, with an emphasis on risk-stratification, highlighting the need for personalized care in order to maximize the benefit of these therapies while minimizing toxicities.
Publisher
American Society of Hematology
Reference58 articles.
1. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms;Khoury;Leukemia,2022
2. Real-world treatments and thrombotic events in polycythemia vera patients in the USA;Verstovsek;Ann Hematol,2023
3. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia;Pemmaraju;Leuk Res,2022
4. Gerds
AT
, GotlibJ, AliH, et al.
Myeloproliferative Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Vols. 2-23. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2023. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed April7, 2023.
5. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet;Barbui;Leukemia,2018